Vimarsana
Biggest News Aggregation in the World

Page 2 - Matthew Ehrhardt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Matthew Ehrhardt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Matthew Ehrhardt Today - Breaking & Trending Today

Ehrhardt Explains the Effects of Modifiable Health Conditions on Late Mortality for Childhood Cancer Survivors - Vimarsana News

Ehrhardt Explains the Effects of Modifiable Health Conditions on Late Mortality for Childhood Cancer Survivors

Dr Ehrhardt discusses how modifiable chronic health conditions may relate to social determinants of health, noting how these factors can potentially lead to late mortality for survivors of childhood cancer.

Childhood cancer survivors maintaining a healthy lifestyle may have lower risk of mortality - Vimarsana News

Childhood cancer survivors maintaining a healthy lifestyle may have lower risk of mortality

A report from the Childhood Cancer Survivor Study provides strong evidence of the importance of a healthy lifestyle for adults who were treated for cancer as children.

Socioeconomic deprivation linked with increased late mortality in childhood cancer survivors - Vimarsana News

Socioeconomic deprivation linked with increased late mortality in childhood cancer survivors

St. Jude Children's Research Hospital scientists have found that socioeconomic deprivation, the presence of treatable chronic health conditions and frailty are independently associated with increased late mortality in childhood cancer survivors.

Excellent outcomes reported for first targeted frontline therapy for high-risk pediatric Hodgkin lymphoma - Vimarsana News

Excellent outcomes reported for first targeted frontline therapy for high-risk pediatric Hodgkin lymphoma

Date Time Excellent outcomes reported for first targeted frontline therapy for high-risk pediatric Hodgkin lymphoma (From left) First and corresponding author Monika Metzger, M.D., Departments of Oncology and Global Pediatric Medicine; co- senior author Matthew Krasin, M.D., Department of Radiation Oncology; and co-senior author Melissa Hudson, M.D., Cancer Survivorship Division director. Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieve...